Literature DB >> 26181868

Involvement of the liver in rheumatic diseases.

Hiromasa Ohira1, Kazumichi Abe2, Atsushi Takahashi2.   

Abstract

Liver dysfunction is often observed in patients with rheumatic diseases. Underlying disease is the major cause of liver dysfunction associated with adult-onset Still's disease, polymyositis/dermatomyositis, and vasculitis syndrome, whereas drug-induced liver injury is common in rheumatoid arthritis and systemic lupus erythematosus. These diseases may be accompanied by autoimmune hepatitis and primary biliary cirrhosis (PBC). PBC is particularly common in CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactylia, and telangiectasia) syndrome and Sjögren's syndrome. The recent widespread use of biological drugs such as tumor necrosis factor inhibitors has raised concerns about reactivation of hepatitis B. Given the varying causes and degrees of liver dysfunction associated with rheumatic diseases, medical intervention should be undertaken with adequate understanding of the characteristics of each type of liver disease.

Entities:  

Keywords:  Autoimmune liver disease; CREST syndrome; Rheumatoid arthritis; Systemic lupus erythematosus

Year:  2011        PMID: 26181868     DOI: 10.1007/s12328-011-0271-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  68 in total

1.  A case of systemic lupus erythematosus complicated by pure red cell aplasia and idiopathic portal hypertension after thymectomy.

Authors:  Haruyo Iwadate; Hiroko Kobayashi; Kiori Shio; Etsuko Noguchi; Kenya Watanabe; Tomomi Sasajima; Hideharu Sekine; Hiroshi Watanabe; Hiromasa Ohira; Katsutoshi Obara; Yukio Sato
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

2.  Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.

Authors:  Pilar Martinez Montiel; Jose Antonio Solis; Juan Antonio Chirinos; Begoń a Casis; Fernando Sánchez; Sarbelio Rodríguez
Journal:  Liver Int       Date:  2008-05       Impact factor: 5.828

3.  Chronic liver disease and Still's disease.

Authors:  J R Tesser; E J Pisko; J W Hartz; M E Weinblatt
Journal:  Arthritis Rheum       Date:  1982-05

4.  Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.

Authors:  Yukitomo Urata; Ryoko Uesato; Dai Tanaka; Kenji Kowatari; Taisuke Nitobe; Yoshihide Nakamura; Shigeru Motomura
Journal:  Mod Rheumatol       Date:  2010-07-29       Impact factor: 3.023

5.  Polymyositis associated with autoimmune hepatitis, primary biliary cirrhosis, and autoimmune thrombocytopenic purpura.

Authors:  Yuko Kurihara; Takashi Shishido; Kayo Oku; Masashi Takamatsu; Hiroshi Ishiguro; Atsushi Suzuki; Tsunejirou Sekita; Toshihito Shinagawa; Tadayuki Ishihara; Ran Nakashima; Takao Fujii; Yutaka Okano
Journal:  Mod Rheumatol       Date:  2011-01-15       Impact factor: 3.023

6.  Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance.

Authors:  Hideyuki Kojima; Masahito Uemura; Shinya Sakurai; Tatsuichi Ann; Yoshinobu Ishii; Hiroo Imazu; Masahide Yoshikawa; Kunio Ichijima; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

7.  Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases.

Authors:  F C Powell; A L Schroeter; E R Dickson
Journal:  Q J Med       Date:  1987-01

8.  Subclinical liver disease in systemic lupus erythematosus.

Authors:  T Gibson; A R Myers
Journal:  J Rheumatol       Date:  1981 Sep-Oct       Impact factor: 4.666

9.  Analysis of B-cell clonality in the hepatic tissue of patients with Sjögren's syndrome.

Authors:  T Tokuno; H Takahashi; C Suzuki; M Yamamoto; Y Naishiro; A Sugaya; H Sakamoto; K Imai
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

10.  Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.

Authors:  Shunsuke Mori
Journal:  Mod Rheumatol       Date:  2011-04-29       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.